| Monoclonaux | SYSTEMES D'EXPRESSION | DOMAINE THERAPEUTIQUE | ||
|---|---|---|---|---|
| CHO | Lignée myélome souris | Cellule de mammifère | ||
| adalimumab | + | Polyarthrite rhumatoïde (PR) | ||
| abciximab | + | Thrombose | ||
| alemtuzumab | + | Leucémie lymphoïde chronique | ||
| basiliximab | + | Transplantation | ||
| bevacizumab | + | Cancer | ||
| cetuximab | + | Cancer | ||
| daclizumab | + | Transplantation | ||
| efalizumab | + | Psoriasis | ||
| gemtuzumab | + | Leucémie aigue myéloblastique | ||
| infliximab | + | PR, Crohn, Spondylarthrite ankylosante | ||
| natalizumab | + | Sclérose en Plaques, Crohn | ||
| omalizumab | + | Asthme | ||
| palivizumab | + | Infection Virus respiratoire syncitial | ||
| rituximab | + | Lymphomes | ||
| trastuzumab | + | Cancer | Protéines de fusion | |
| etanercept | + | PR, Spondylarthrite ankylosante, Psoriasis | ||
| alefacept | + | Psoriasis |
